PP-104 Acute Inferior Myocardial Infarction in a Patient Undergoing Rivaroxaban Therapy
Introduction The novel oral anticoagulant agents (NOACs) provide compelling evidence-based advances over warfarin therapy in non-valvular atrial fibrillation (AF) and have received endorsement from contemporary guidelines. Rivaroxaban, one of these…